Correction: Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000313corr1.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
by: Celeste Lebbe, et al.
Published: (2020-05-01) -
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
by: Sonja Levy, et al.
Published: (2020-10-01) -
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
by: Celeste Lebbe, et al.
Published: (2020-05-01) -
Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
by: Andrew Nguyen, et al.
Published: (2020-10-01) -
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01)